Gano Kyle 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) CEO Kyle Gano Exercises RSUs; Shares Withheld
What Happened
Kyle Gano, CEO of Neurocrine Biosciences (NBIX), had a tranche of restricted stock units (RSUs convert/settle) on January 31, 2026. The filing shows conversion/settlement of 2,927 RSUs (reported as derivative exercise/conversion). To satisfy tax withholding on the vesting, 1,580 shares were withheld at a per-share value of $136.06 (total reported value withheld $214,975). Net shares delivered to Gano were approximately 1,347 (2,927 converted minus 1,580 withheld). This was a vesting/settlement and tax-withholding event, not an open-market sale or purchase.
Key Details
- Transaction date: January 31, 2026. Filing date: February 3, 2026.
- Conversion/settlement: 2,927 RSUs converted to common shares (reported as code M). Withholding/disposition: 1,580 shares withheld (code F) at $136.06/share = $214,975.
- Net shares delivered to insider: ~1,347 shares (2,927 − 1,580).
- Footnotes: F1 — shares were withheld by the company to satisfy tax withholding; F2 — each RSU equals one share on settlement; F3 — the RSU award was granted Jan 31, 2022 and vested in annual tranches (2023–2026).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No late-filing flag was noted in the provided data.
Context
This was a routine RSU vesting and tax-withholding transaction (not a market sale). Withholding of shares to cover taxes is common and should not be read as a directional buy/sell signal. For investors, outright purchases by insiders tend to carry more informational weight; this filing documents compensation vesting and tax settlement.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-01-31+2,927→ 143,334 total - Tax Payment
Common Stock
[F1]2026-01-31$136.06/sh−1,580$214,975→ 141,754 total - Exercise/Conversion
Restricted Stock Unit
[F2][F3]2026-01-31−2,927→ 0 total→ Common Stock (2,927 underlying)
Footnotes (3)
- [F1]Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- [F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award.